ClinicalTrials.gov
ClinicalTrials.gov Menu

Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00144638
Recruitment Status : Completed
First Posted : September 5, 2005
Last Update Posted : September 5, 2005
Sponsor:
Information provided by:
Danish Procalcitonin Study Group

Brief Summary:

Procalcitonin, a marker of infection has often been compared to clinical pictures as for instance "clinical sepsis". This has given som problems in the interpretation of these studies, because of the lack of good Gold Standards for "clinical sepsis. We have decided to investigate the development from day to day of Procalcitonin in the blood of intensive care patients, compared to the mortality.

Hypothesis: Procalcitonin increase after reaching a certain level predicts mortality in the Intensive Care Unit.


Condition or disease
Sepsis - to Reduce Mortality in the Intensive Care Unit

  Show Detailed Description

Study Type : Observational
Enrollment : 450 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality
Study Start Date : January 2002
Study Completion Date : January 2003




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Admitted to the ICU 4131 of Rigshospitalet Copenhagen University Hospital in the year 2002

Exclusion Criteria:

Recent (< 3 months) liver transplantation

Expected admission < 24 h


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00144638


Locations
Denmark
Dept. 4131, Rigshospitalet, Cph University Hosp., DK
Copenhagen, Denmark, DK-2100
Sponsors and Collaborators
Danish Procalcitonin Study Group
Investigators
Principal Investigator: Lars Heslet, MD, MD.Sc. Dept. 4131, Rigshospitalet, Blegdamsvej 9, DK-2100

ClinicalTrials.gov Identifier: NCT00144638     History of Changes
Other Study ID Numbers: DPSG1
First Posted: September 5, 2005    Key Record Dates
Last Update Posted: September 5, 2005
Last Verified: February 2005

Additional relevant MeSH terms:
Critical Illness
Disease Attributes
Pathologic Processes
Calcitonin
Bone Density Conservation Agents
Physiological Effects of Drugs